Ngā hua rapu - Laurent Greillier
- E whakaatu ana i te 1 - 20 hua o te 37
- Haere ki te Whārangi Whai Ake
-
1
-
2
-
3
-
4
Personalised medicine for nonsmall cell lung cancer mā Céline Mascaux, Pascale Tomasini, Laurent Greillier, Fabrice Barlési
I whakaputaina 2017Revisão -
5
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases mā Pascale Tomasini, Julie Egea, M. Souquet-Bressand, Laurent Greillier, Fabrice Barlési
I whakaputaina 2019Revisão -
6
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma mā Laurent Greillier, A. Cavaillès, A. Fraticelli, Arnaud Scherpereel, Fabrice Barlési, Gianfranco Tassi, P. Thomas, Philippe Astoul
I whakaputaina 2007Artigo -
7
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer mā Fabrice Barlési, Céline Gimenez, Jean-Philippe Torre, C. Doddoli, Julien Mancini, Laurent Greillier, François Roux, J P Kleisbauer
I whakaputaina 2003Artigo -
8
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderl... mā Athanasios Pallis, Cesare Gridelli, Jan P. van Meerbeeck, Laurent Greillier, Ulrich Wedding, Didier Lacombe, John J. Welch, Chandra P. Belani, Matti Aapro
I whakaputaina 2009Revisão -
9
EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer mā Pascale Tomasini, Cindy Serdjebi, Nataliya Khobta, Philippe Métellus, L’Houcine Ouafik, Isabelle Nanni, Laurent Greillier, Anderson Loundou, Frédéric Fina, Céline Mascaux, Fabrice Barlési
I whakaputaina 2016Artigo -
10
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer mā M. Grangeon, Pascale Tomasini, S. Chaléat, A. Jeanson, M. Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, M. Blanchon, Mohamed Boucékine, Céline Mascaux, Fabrice Barlési
I whakaputaina 2018Artigo -
11
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expre... mā Clémence Demerle, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frédéric Di Fiore, Jacques A. Nunès, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Hervé Luche, Fabrice Barlési, Daniel Olive
I whakaputaina 2023Artigo -
12
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cance... mā Antonin Lévy, Corinne Faivre‐Finn, Baktiar Hasan, Eléonora De Maio, Anna S. Berghoff, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, Mary O’Brien, Martin Reck, Anne‐Marie C. Dingemans, Silvia Novello, Thierry Berghmans, Benjamin Besse, Lizza Hendriks
I whakaputaina 2018Artigo -
13
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) mā A. Jeanson, Pascale Tomasini, M. Souquet-Bressand, Nicolas Brandone, Mohamed Boucékine, M. Grangeon, S. Chaléat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Julie Biemar, Isabelle Nanni, L’Houcine Ouafik, Stéphane Garcia, Julien Mazières, Fabrice Barlési, Céline Mascaux
I whakaputaina 2019Artigo -
14
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY... mā Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana‐Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone
I whakaputaina 2019Artigo -
15
A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC mā Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan M. Lehman, Daniel Morgensztern, Jyoti D. Patel, John M. Wrangle, Giuseppe Curigliano, Laurent Greillier, Melissa L. Johnson, Neal Ready, G. Robinet, Satwant Lally, David Maag, Ricardo Santoyo Valenzuela, Vincent Blot, Benjamin Besse
I whakaputaina 2021Artigo -
16
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease mā Antonin Lévy, Lizza Hendriks, Thierry Berghmans, Corinne Faivre‐Finn, Matteo Giaj Levra, Niccolò Giaj-Levra, Baktiar Hasan, Alessia Pochesci, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, John Edwards, Mary O’Brien, Martin Reck, Benjamin Besse, Silvia Novello, Anne‐Marie C. Dingemans
I whakaputaina 2019Artigo -
17
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers mā Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Júlio Oliveira, Laurent Greillier, Judith Raimbourg, Anne‐Claire Toffart, Thierry Chatellier, Nicolas Cloarec, Ivana Sullivan, Birute Brasiūnienė, M. Duruisseaux, Kersti Oselin, Marie-Sophie Robert, C. Fernandes, Arnaud Poncin, Jean‐Yves Blay, Benjamin Besse, Nicolas Girard
I whakaputaina 2024Artigo -
18
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial mā Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, Emmanuel Grolleau, Massimo Bernardi, S. Hominal, Jean.Briac Prevost, G. Pamart, Marie.Héléne Marques, Nicolas Cloarec, S. Deshayes, Judith Raimbourg, Rémi Veillon, Youssef Oulkhouir, Clarisse Audigier-Valette, Fabien Subtil, C. Chouaïd, Laurent Greillier
I whakaputaina 2024Artigo -
19
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio... mā Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Julien Mazières, Sylvie Lantuéjoul, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, V. Gounant, Martine Antoine, Denis Moro‐Sibilot, Isabelle Rouquette, Olivier Molinier, R. Corre, Isabelle Monnet, Alexandra Langlais, Franck Morin, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet
I whakaputaina 2019Artigo -
20
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 mā Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, Paul Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, X. Zhang, Nan Hu, David Balli, Thomas E. Spires, Gérard Zalcman
I whakaputaina 2022Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Oncology
Cancer
Lung cancer
Chemotherapy
Immunotherapy
Pathology
Biology
Nivolumab
Clinical trial
Ipilimumab
Surgery
Cancer research
Cisplatin
Mesothelioma
Gene
Pemetrexed
Adverse effect
Biochemistry
Confidence interval
Gastroenterology
Hazard ratio
Radiation therapy
Atezolizumab
Clinical endpoint
Colorectal cancer
Disease
Immunohistochemistry
Immunology